Drug
Valemetostat tosylate clinical trials
Also written DS-3201b.
A product of Valemetostat; its studies count on that page too.
Keep track of what changes. Save the valemetostat tosylate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
10 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 3 |
| 2021 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 4
Daiichi Sankyo (4) · Daiichi Sankyo Co., Ltd. (2) · The Lymphoma Academic Research Organisation (1) · Alliance for Clinical Trials in Oncology (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Carboplatin (1) · Cabazitaxel (1) · Abiraterone Acetate (1) · Abiraterone (1) · Enzalutamide (1) · Lutetium (¹⁷⁷Lu) vipivotide tetraxetan (1) · Irinotecan (1)
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Valemetostat
Studies
Open first, then newest update. How each study uses valemetostat tosylate is read from its arms, and is right about nine times in ten.
Testing it · 10
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT06632977Written as Valemetostat Tosylate
- Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.RecruitingPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT07303387Written as Valemetostat Tosylate
- A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic AlterationsActive, not recruitingPhase 1/2Daiichi SankyoNCT06644768Written as valemetostat tosylate
- Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)Active, not recruitingPhase 2Daiichi SankyoNCT04703192Written as Valemetostat Tosylate
- DS-3201b in Participants With LymphomasActive, not recruitingPhase 1Daiichi Sankyo Co., Ltd.NCT02732275Written as DS-3201b
- Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell LymphomaActive, not recruitingPhase 2The Lymphoma Academic Research OrganisationNCT04842877Written as Valemetostat tosylate
- Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/LymphomaCompletedPhase 2Daiichi Sankyo Co., Ltd.NCT04102150Written as Valemetostat Tosylate
- DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung CancerTerminatedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT03879798Written as DS-3201b
- DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)TerminatedPhase 1Daiichi SankyoNCT03110354Written as DS-3201b
- Study of Single-dose DS-3201b in Participants With Hepatic ImpairmentCompletedPhase 1Daiichi SankyoNCT04276662Written as DS-3201b
Given in every arm · 1 — valemetostat tosylate is usual care beside what is tested
Codes
What other systems call valemetostat tosylate · ClinicalTrials.gg INT015300
- UNII (FDA) 6N79I7X5IIVALEMETOSTAT TOSYLATEOne source FDA
- NCI Thesaurus C168589Valemetostat TosylateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6N79I7X5II | VALEMETOSTAT TOSYLATE | One source FDA |
| NCI Thesaurus | C168589 | Valemetostat Tosylate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.